Xilio Therapeutics Faces Delisting Notice
Ticker: XLO · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1840233
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Xilio's getting kicked off the exchange, big trouble.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on October 3, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 828 Winter Street, Waltham, Massachusetts.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to its operations and shareholder value.
Key Numbers
- 001-40925 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1623397 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- October 2, 2025 (date) — Earliest event reported
- October 3, 2025 (date) — Filing date
- 828 Winter Street, Waltham, Massachusetts 02451 (address) — Principal Executive Offices
FAQ
What is the specific reason for Xilio Therapeutics' potential delisting?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule violated.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 2, 2025.
What is Xilio Therapeutics' principal executive office address?
The principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the company's SEC file number?
The SEC file number for Xilio Therapeutics, Inc. is 001-40925.
What is the filing date of this 8-K report?
This 8-K report was filed on October 3, 2025.
Filing Stats: 642 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2025-10-03 07:30:14
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
- $1.00 m — Company of its failure to maintain the $1.00 minimum bid price required for continued
- $1.00 — he Company's common stock must close at $1.00 or more for at least 10 consecutive bus
Filing Documents
- d74952d8k.htm (8-K) — 24KB
- 0001193125-25-229231.txt ( ) — 139KB
- xlo-20251002.xsd (EX-101.SCH) — 3KB
- xlo-20251002_lab.xml (EX-101.LAB) — 18KB
- xlo-20251002_pre.xml (EX-101.PRE) — 11KB
- d74952d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: October 3, 2025 By: /s/ Caroline Hensley Caroline Hensley Chief Legal Officer